Krishna Komanduri, Medical Director, Living Therapeutics Initiative at University of California, San Francisco, shared National Cancer Institute (NCI)’s, post on LinkedIn:
“Important story of how an ‘undruggable’ oncogene, RAS, contributes to cancer evolution and can now be targeted therapeutically and how funding from National Cancer Institute (NCI) made this advance possible.
Three individuals with University of California, San Francisco ties are featured in this story including The Nobel Prize winner and former The National Institutes of Health Director Harold Varmus, former UCSF Helen Diller Family Comprehensive Cancer Center Director Frank McCormick and Kevan Shokat, whose work to develop RAS G12C and other inhibitors led to the development of Daraxonrasib and related drugs for pancreatic cancer.
We have been talking about personalized and targeted cancer therapies for many years, but we are truly entering into a new era of hope and possibility as basic scientific advances are being translated to therapies before our eyes. Proud to be at an institution that inspires hope and possibility.”
Quoting National Cancer Institute (NCI):
“Learn the story of RAS, one of the most commonly mutated genes in cancer, and the decades of research that helped turn a once-frustrating target into an area of real progress.
NCI-supported research helped build the foundation for what scientists know about RAS today. In 2013, NCI launched the RAS Initiative at Frederick National Laboratory for Cancer Research, bringing together researchers from government, academia, and industry to tackle a challenge that had resisted progress for years.
The RAS story is a reminder that sustained investment in basic research, paired with collaboration, can open doors that once seemed closed.”
You can also read: Phase 3 RASolute 309 Trial Begins: RASONQUE Plus Zoldonrasib in First-Line RAS G12D PDAC
